ClinicalTrials.gg
CompletedNCT00427921ACCESSUpdated Nov 20, 2009Results posted

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

A Phase 3 interventional study of adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
6th of 42
304 · median 143
Started
2007
with 3 others
Phase 3
22 of 42
none open now
Registered
10th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 6th largest by enrollment, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 10th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

To make adalimumab available to subjects suffering from moderately to severely active Crohn's Disease (CD) and to expand the safety information on adalimumab. The study also assessed changes in Patient Reported Outcome Measures from baseline.

Read the detailed description

This was a Phase 3, multicenter, open-label, Early Access Study with an induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4 in subjects with moderately to severely active Crohn's Disease (CD) who were eligible to receive biologic therapy or who had failed to respond to, lost response to, or were intolerant to infliximab. Failure of prior therapy was determined by the Investigator. Subjects were to have an 8-week wash-out period prior to Baseline from the last dose of infliximab.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 years of age and older
  • Females: Not of OR Practicing approved throughout the study and for 150 days after study completion
  • Diagnosis of moderate to severe CD for greater than 16 weeks prior to screening; Crohn's Disease Activity Index score > 220 OR Harvey Bradshaw Index equal to or higher than 7, and who are to optimal conventional therapies such as, 5-aminosalicylic acid (5-ASA), , and therapies (azathioprine, 6-MP and MTX)
  • Subjects who failed prior infliximab therapy (as determined by the primary investigator), including those who never clinically responded ("primary non-responders")

Exclusion criteria

Exclusion Criteria:

  • History of cancer other than some skin and cervical cancers
  • History of opportunistic infections, central nervous system (CNS) demyelinating disease, chronic viral hepatitis, or untreated tuberculosis
  • Subjects with other, poorly controlled medical conditions
  • Subjects with any prior exposure to Tysabri® (natalizumab)
  • Subjects who have received any agent in the past 30 days or 5 half-lives prior to screening (whichever is longer)
  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    1

    Open Label

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    160 mg loading dose, 80 mg at week 2, 40 mg every other week

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Mean Extent of Exposure - Duration in Days

    Extent of exposure for all adalimumab treated subjects

    Time frame: Up to 24 weeks

  2. Total Number of Injections of Adalimumab

    Extent of exposure for all adalimumab treated subjects

    Time frame: Up to 24 weeks

  3. Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.

    Treatment compliance (%) = 100 \* (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).

    Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.

    Time frame: Week 12, Week 24, and Last Assessment Value (last nonmissing value)

  2. Overall Health Care Resource Utilization

    From the "Overall Health Care Resource Utilization Questionnaire": Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.

    Time frame: Up to 24 weeks

  3. Employment Status: Number of Subjects Employed

    Summary of employment status of those employed.

    Time frame: Baseline, Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)

  4. 50% Improvement in Draining Fistula Count and Fistula Healing

    Decrease in draining fistula is beneficial. "50 percent improvement" refers to a reduction in the number of baseline fistula by 50 percent.

    Time frame: Week 12, Week 24, Last Assessment Value (last nonmissing value)

  5. Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment

    Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity). Minimal clinically important difference = 7 points. Measure is Mean percent change.

    Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)

  6. Hematology - Change From Baseline to Final Visit

    Changes from the Group mean at baseline are compared to the final visit Group mean value

    Time frame: Up to 24 weeks

  7. Clinical Chemistry - Change From Baseline to Final Visit

    Changes from the Group mean at Baseline are compared to the final visit Group mean value

    Time frame: Up to 24 weeks

  8. Urinalysis - Change From Baseline to Final Visit

    Changes from the Group mean at baseline are compared to the final visit Group mean value

    Time frame: Up to 24 weeks

  9. Work Productivity and Activity Impairment - Change From Baseline in Absenteeism

    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

    Time frame: Weeks 4, 8, 12, and 24, and Last Assessmentl Value (last nonmissing value)

  10. Work Productivity and Activity Impairment - Change From Baseline in Presenteeism

    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

    Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)

  11. Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment

    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

    Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)

07

Results

Posted Oct 23, 2009
Limitations and caveats
Subjects who failed prior infliximab therapy were eligible to enter study after minimum 8 week wash-out since last dose. Includes subjects who previously used infliximab \& never responded or responded \& developed intolerance/lost efficacy.

Participant flow

Participant flow — Overall Study
Milestone40 mg Adalimumab Every Other Week
Started304
Completed254
Not completed50
Withdrew: Adverse event26
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up2
Withdrew: Other reason not specified10
Withdrew: Adverse event + hospitalization1
Withdrew: Adverse event + withdrew consent1
Withdrew: Adverse event + no response1
Withdrew: Adverse event + worsening of cd1
Withdrew: Adverse event + no therapeutic benefit1
Withdrew: Adverse event + lost response1
Withdrew: Adverse event + withdrawn from study1
Withdrew: Withdrew consent + lack of efficacy1

Outcome measures

PrimaryMean Extent of Exposure - Duration in Days

Extent of exposure for all adalimumab treated subjects

Time frame:
Up to 24 weeks
Reported as:
Mean · days
Mean Extent of Exposure - Duration in Days
days40 mg Adalimumab Every Other Week
Mean Extent of Exposure - Duration in Days159.2 ± 34.78
Post-hocHarvey-Bradshaw Index (HBI) Mean Change From Baseline

HBI score (range 0-30) sum subtotal of 5 parameters of subject's CD activity: a)Well being 0=very well-4=terrible b) Abdominal pain 0=none- 3=severe c) Number liquid stools per day d) Abdominal mass 0=none-3=tender e) Complications: 1 point each. Decrease indicates improvement. Absolute decrease of 3 units on scale is clinically important.

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · Units on scale
Harvey-Bradshaw Index (HBI) Mean Change From Baseline
Units on scale40 mg Adalimumab Every Other Week
Week 4-4.39 (-4.94 to -3.84)
Week 8-4.53 ± 5.175
Week 12-5.32 ± 5.008
Week 24-6.36 ± 5.031
Last Assessment Value-5.92 ± 5.162
SecondaryFistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).

Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.

Time frame:
Week 12, Week 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · number of fistulas
Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).
number of fistulas40 mg Adalimumab Every Other Week
Week 12-0.17 ± 0.644
Week 24-0.15 ± 0.587
Last Assessment Value-0.15 ± 0.567
PrimaryTotal Number of Injections of Adalimumab

Extent of exposure for all adalimumab treated subjects

Time frame:
Up to 24 weeks
Reported as:
Mean · injections
Total Number of Injections of Adalimumab
injections40 mg Adalimumab Every Other Week
Number of Injections During Induction Therapy2 ± 0.1
Number of Injections During Maintenance Therapy11.8 ± 4.24
PrimaryCompliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.

Treatment compliance (%) = 100 \* (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).

Time frame:
Up to 24 weeks
Reported as:
Mean · Percentage of injections
Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.
Percentage of injections40 mg Adalimumab Every Other Week
Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.98.85 ± 4.207
Post-hocShort Inflammatory Bowel Disease Questionnaire (SIBDQ) Mean Change From Baseline

Quality of life questionnaire for patients with IBD consisting of 4 domains: systemic, social, emotional, and bowel. This is a 10-item questionnaire, and all items are reported with a 7-point scale (ranging from 1 = poor HRQOL, to 7 = optimum HRQOL). Total SIBDQ score ranges from 10 (quality of life has been negatively affected tremendously by IBD) to 70 (quality of life is barely impacted by IBD). A change greater than 9 points was the minimal clinically important difference (MCID).

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · units on a scale
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Mean Change From Baseline
units on a scale40 mg Adalimumab Every Other Week
Week 410.16 ± 10.692
Week 811.85 ± 11.591
Week 1213.14 ± 11.783
Week 2415.06 ± 12.209
Last Assessment Value13.74 ± 12.629
SecondaryOverall Health Care Resource Utilization

From the "Overall Health Care Resource Utilization Questionnaire": Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.

Time frame:
Up to 24 weeks
Reported as:
Mean · number of visits
Overall Health Care Resource Utilization
number of visits40 mg Adalimumab Every Other Week
Number of visits to a physician1.13 ± 2.794
Number of visits to Emergency Room0.17 ± 0.522
Number of hospital admissions0.10 ± 0.346
Number of days of hospitalizations0.60 ± 2.790
SecondaryEmployment Status: Number of Subjects Employed

Summary of employment status of those employed.

Time frame:
Baseline, Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Number · participants
Employment Status: Number of Subjects Employed
participants40 mg Adalimumab Every Other Week
Baseline195 ± 64.1
Week 4199
Week 8198
Week 12192
Week 24190
Last Assessment Value208
Secondary50% Improvement in Draining Fistula Count and Fistula Healing

Decrease in draining fistula is beneficial. "50 percent improvement" refers to a reduction in the number of baseline fistula by 50 percent.

Time frame:
Week 12, Week 24, Last Assessment Value (last nonmissing value)
Reported as:
Number · participants
50% Improvement in Draining Fistula Count and Fistula Healing
participants40 mg Adalimumab Every Other Week
Week 12 50% Improvement in draining fistula35
Week 24 50% Improvement in draining fistula31
Last Value 50% Improvement in draining fistula32
Week 12 Fistula Healing23
Week 24 Fistula Healing27
Last Assessment Value Fistula Healing28
SecondaryWork Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment

Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity). Minimal clinically important difference = 7 points. Measure is Mean percent change.

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · Units on scale
Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment
Units on scale40 mg Adalimumab Every Other Week
Week 4-22.08 ± 28.454
Week 8-22.36 ± 29.337
Week 12-29.93 ± 33.669
Week 24-31.23 ± 30.403
Last Assessment Value-28.49 ± 32.286
SecondaryHematology - Change From Baseline to Final Visit

Changes from the Group mean at baseline are compared to the final visit Group mean value

Time frame:
Up to 24 weeks
Reported as:
Mean · number
Hematology - Change From Baseline to Final Visit
number40 mg Adalimumab Every Other Week
Hemoglobin (g/L)2.2 ± 12.43
Hematocrit (fraction)0.011 ± 0.0376
Red blood cell count (x10^9/L)0.03 ± 0.353
Platelet Count (x10^9/L)-30.2 ± 89.28
White blood cell count (x10^9/L)-1.59 ± 3.297
Neutrophils (x10^9/L)-2.005 ± 3.1777
Lymphocytes (x10^9/L)0.408 ± 0.7285
Monocytes (x10^9/L)-0.014 ± 0.1725
Eosinophils (x10^9/L)0.009 ± 0.1505
Basophils (x10^9/L)-0.015 ± 0.0617
SecondaryClinical Chemistry - Change From Baseline to Final Visit

Changes from the Group mean at Baseline are compared to the final visit Group mean value

Time frame:
Up to 24 weeks
Reported as:
Mean · number
Clinical Chemistry - Change From Baseline to Final Visit
number40 mg Adalimumab Every Other Week
SGPT/ALT (U/L)0.6 ± 17.89
SGOT/ALT (U/L)1.6 ± 10.35
Alkaline phosphatase (U/L)-5.2 ± 21.53
Total Bilirubin (mcmol/L)1.6 ± 4.06
Creatinine (mcmol/L)1.7 ± 10.35
BUN (mmol/L)0.06 ± 1.367
Uric acid (mcmol/L)4.6 ± 52.38
Inorganic phosphate0.016 ± 0.2588
Calcium (mmol/L)0.008 ± 0.1189
Sodium (mmol/L)-0.3 ± 2.38
Potassium (mmol/L)-0.00 ± 0.779
Albumin (G/L)0.4 ± 4.01
Total protein (G/L)0.8 ± 4.83
Cholesterol (mmol/L)0.021 ± 0.7024
Triglycerides (mmol/L)0.093 ± 0.7581
C-reactive protein (mg/L)-8.181 ± 28.7023
Glucose - fasting (mmol/L)-0.268 ± 1.3893
SecondaryUrinalysis - Change From Baseline to Final Visit

Changes from the Group mean at baseline are compared to the final visit Group mean value

Time frame:
Up to 24 weeks
Reported as:
Mean · number
Urinalysis - Change From Baseline to Final Visit
number40 mg Adalimumab Every Other Week
Urine pH0.02 ± 0.980
Specific gravity-0.0004 ± 0.00713
SecondaryWork Productivity and Activity Impairment - Change From Baseline in Absenteeism

The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessmentl Value (last nonmissing value)
Reported as:
Mean · units on a scale
Work Productivity and Activity Impairment - Change From Baseline in Absenteeism
units on a scale40 mg Adalimumab Every Other Week
Week 4-5.99 ± 24.592
Week 8-7.55 ± 27.543
Week 12-8.74 ± 33.477
Week 24-8.54 ± 27.260
Last Assessment Value-6.46 ± 29.167
SecondaryWork Productivity and Activity Impairment - Change From Baseline in Presenteeism

The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · Units on scale
Work Productivity and Activity Impairment - Change From Baseline in Presenteeism
Units on scale40 mg Adalimumab Every Other Week
Week 4-20.58 ± 26.115
Week 8-19.94 ± 27.151
Week 12-25.79 ± 30.113
Week 24-28.96 ± 28.472
Last Assessment Value-26.69 ± 30.058
SecondaryWork Productivity and Activity Impairment - Change From Baseline in Activity Impairment

The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.

Time frame:
Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Reported as:
Mean · Units on scale
Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment
Units on scale40 mg Adalimumab Every Other Week
Week 4-23.59 ± 26.928
Week 8-24.79 ± 28.431
Week 12-30.36 ± 28.697
Week 24-34.00 ± 29.552
Last Assessment Value-30.98 ± 30.484

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40 mg Adalimumab Every Other Week———
Most frequent serious events
Showing 10 of 33
Most frequent serious events
Event40 mg Adalimumab Every Other Week
Crohn's DiseaseGastrointestinal disorders13/304
small intestinal obstructionGastrointestinal disorders9/304
abdominal abscessInfections and infestations4/304
anaemiaBlood and lymphatic system disorders3/304
abdominal painGastrointestinal disorders2/304
subileusGastrointestinal disorders2/304
heparin-induced thrombocytopeniaBlood and lymphatic system disorders1/304
atroventricular block completeCardiac disorders1/304
GI haemorrhageGastrointestinal disorders1/304
GI motility disorderGastrointestinal disorders1/304
Most frequent other events
Most frequent other events
Event40 mg Adalimumab Every Other Week
Crohn's DiseaseGastrointestinal disorders49/304
Abdominal painGastrointestinal disorders23/304
Injection site reactionGeneral disorders23/304
NauseaGastrointestinal disorders19/304
HeadacheNervous system disorders19/304
ArthralgiaMusculoskeletal and connective tissue disorders18/304
NasopharyngitisInfections and infestations15/304
FatigueGeneral disorders14/304

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)40 mg Adalimumab Every Other Week
<=18 years0
Between 18 and 65 years296
>=65 years8
Sex: Female, Male
Sex: Female, Male(Participants)40 mg Adalimumab Every Other Week
Female173
Male131
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)40 mg Adalimumab Every Other Week
American Indian or Alaska Native2
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White291
More than one race1
Unknown or Not Reported6
Hispanic0
Region of Enrollment
Region of Enrollment(Participants)40 mg Adalimumab Every Other Week
Canada304
Alcohol
Alcohol(participants)40 mg Adalimumab Every Other Week
User147
Ex-User15
Non-User142
C-Reactive protein mg/dL
C-Reactive protein mg/dL(participants)40 mg Adalimumab Every Other Week
< 1.0 mg/dL148
> = 1.0 mg/dL155
Missing1
Nicotine
Nicotine(participants)40 mg Adalimumab Every Other Week
User98
Ex-User84
Non-User122
Number Subjects With Draining Cutaneous Fistulas at Screening
Number Subjects With Draining Cutaneous Fistulas at Screening(participants)40 mg Adalimumab Every Other Week
Count 0 lesions235
Count 1 lesion42
Count 2 lesions16
Count 3 lesions5
Count >=4 lesions5
Missing1

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Global Medical Information - Abbott
    Abbott Park, Illinois 60064, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2007
First posted
Jan 29, 2007
Start
Jan 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Oct 23, 2009
Last update
Nov 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00427921
Lead sponsor
Abbott
First posted
Jan 29, 2007
Start date
Jan 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Oct 23, 2009
Last update
Nov 20, 2009

Study contacts

Jimmy Baloukas
study director · Abbott
Remo Panaccione, MD, FRCPC
study chair · Director, Inflammatory Bowel Disease Clinic, Associate Professor of Medicine, University of Calgary, Calgary, AB, Canada

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion